Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer

Background Pathologic complete response (pCR) after preoperative systemic chemotherapy (PSCh) is associated with better outcome in locally advanced breast cancer (LABC). Patients and methods PSCh included: doxorubicin (A) 50 mg/m 2 i.v. on day 1; docetaxel (T) 30 mg/m 2 i.v. on days 1, 8 and 15; and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer (Tokyo, Japan) Japan), 2010-07, Vol.17 (3), p.205-211
Hauptverfasser:	Manga, Gumersindo Pérez, Shahi, Parham Khosravi, Ureña, Miguel Méndez, Pereira, Rosa Quiben, Plaza, María Isabel Palomero, Peron, Yann Izarzugaza, Val, Ricardo González Del, Carrión, Joaquín Belón, Cañón, Esperanza Pérez, Alfonso, Pilar García
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Analysis Antimitotic agents Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - immunology Breast Neoplasms - pathology Cancer Cancer Research Capecitabine Carcinoma, Ductal, Breast - drug therapy Carcinoma, Ductal, Breast - immunology Carcinoma, Ductal, Breast - pathology Carcinoma, Lobular - drug therapy Carcinoma, Lobular - immunology Carcinoma, Lobular - pathology Chemotherapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Doxorubicin - administration & dosage Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Follow-Up Studies Humans Medicine Medicine & Public Health Middle Aged Neoadjuvant Therapy Oncology Original Article Preoperative Care Remission Induction Surgery Surgical Oncology Survival Rate Taxoids - administration & dosage Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!